Tonix Pharmaceuticals has reiterated its commitment to advance development of its live attenuated virus vaccine, TNX-801, for preventing mpox and other infectious diseases. On August 14, 2024, the World Health Organization, WHO, determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern, the second such declaration in the past two years called in response to an mpox outbreak. The current outbreak was caused by Clade 1 monkeypox virus, while the 2022 outbreak was Clade 2 monkeypox virus. Tonix’s live virus vaccine candidate, TNX-801, is designed to provide long-term protection from mpox and smallpox with one dose. TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with intratracheal monkeypox virus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
- Tonix Pharma’s Promising Fibromyalgia Treatment Insights
- Tonix Pharmaceuticals presents data on TNX-102 SL treatment
- Tonix Pharmaceuticals announces publication on antibodies against SARS-CoV-2
- Tonix Pharmaceuticals announces potential impact from long COVID